FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
AdComderamiocelNegative
AI Analysis
Summary
The FDA has disputed Capricor's claims that its Phase 3 trial for deramiocel met primary endpoints in DMD treatment. The disagreement was detailed in briefing documents ahead of an advisory committee meeting.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
FDA disagreed with Capricor's assertion that Phase 3 trial met primary outcome measures
Importance:8/10
Sentiment:
-0.80
FDAadvisory committeecell therapyDMDregulatory challenge
Related Companies
Read the original article
Published by BioSpace on July 27, 2026 3:40 PM